The takeover extends a string of deals that have consolidated the outreach lab services market.

Since acquiring the 40-acre property, Sitex Group has been busy updating Zuckerberg's Industrial Park in Saddle Brook to ...

Bio-Rad Laboratories, Inc. (NYSE:BIO) is scheduled to announce Q3 earnings results on Wednesday, October 29th, after market close. The consensus EPS Estimate is $1.93 (-4.0% Y/Y) and the consensus ...

Bio-Rad Laboratories (BIO) has expanded its collaboration with Biodesix, aiming to clinically validate and pursue regulatory approval for cancer biomarker diagnostic assays. The partnership highlights ...

Bio-Rad Laboratories (BIO) came out with quarterly earnings of $2.26 per share, missing the Zacks Consensus Estimate of $2.3 per share. This compares to earnings of $2.01 per share a year ago. These ...

Upslope Capital Management, an investment management company, released its third-quarter investor letter. A copy of the letter can be downloaded here. The third quarter was a strong one for the fund ...

Fintel reports that on October 30, 2025, Wells Fargo maintained coverage of Bio-Rad Laboratories (NYSE:BIO.B) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 21.85% Upside As of ...

Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without ...

(MENAFN- GlobeNewsWire - Nasdaq) Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE ...

LOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which ...

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the ...